CoChat

Kalopanaxsaponin A ameliorates experimental colitis in mice by inhibiting IRAK‐1 activation in the NF‐κB and MAPK pathways

Open access
Joh, Eun‐Ha, Kim, Dong‐Hyun · 2011 · British Journal of Pharmacology
Cited by 57

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND PURPOSE Kalopanaxsaponin A, a triterpenoid saponin isolated from Kalopanax pictus (family Araliaceae), potently inhibited nuclear factor‐kappa B (NF‐κB) activation in lipopolysaccharide (LPS)‐stimulated peritoneal macrophages during a screening programme for anti‐colitis agents from natural products. Its anti‐inflammatory mechanism remains unknown. Therefore, we investigated its anti‐inflammatory effects in lipopolysaccharide (LPS)‐ or peptidoglycan‐stimulated murine peritoneal macrophages and trinitrobenzene sulphonic acid (TNBS)‐induced colitic mice. EXPERIMENTAL APPROACH Peritoneal macrophages from male ICR mice were stimulated with LPS or peptidoglycan in vitro and treated with kalopanaxsaponin A. Colitis was induced in vivo by intrarectal administration of TNBS in male ICR mice. Mice were treated daily with kalopanaxsaponin A, sulphasalazine or phosphate‐buffered saline. Inflammatory markers, cytokines, enzymes and transcription factors were measured by ELISA, immunoblot, flow cytometry and immunofluorescent confocal microscopy. KEY RESULTS Kalopanaxsaponin A potently inhibited the expression of the pro‐inflammatory cytokines, interleukin (IL)‐1β, tumour necrosis factor (TNF)‐α and IL‐6, induced by LPS, but not that induced by TNF‐α, in peritoneal macrophages. However, it potently increased the expression of the anti‐inflammatory cytokine IL‐10. Kalopanaxsaponin A inhibited activation of the IL‐1 receptor‐associated kinase (IRAK)‐1, inhibitor of κB kinase‐β, NF‐κB and mitogen‐activated protein kinases (extracellular signal‐regulated kinase, c‐Jun NH 2‐terminal kinase, p‐38), but LPS/Toll‐like receptor‐4 interaction and IRAK‐4 activation were not affected. Oral administration of kalopanaxsaponin A (10 and 20 mg·kg−1) improved the clinical parameters and histology in vivo. Kalopanaxsaponin A inhibited NF‐κB and mitogen‐activated protein kinase activation induced by TNBS by suppressing IRAK‐1 activation. CONCLUSIONS AND IMPLICATIONS Kalopanaxsaponin A may improve inflammatory diseases, such as colitis, by inhibiting IRAK‐1 activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2010.01195.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 57

Metadata

Authors
Joh, E., & Kim, D.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2011-03-22
Volume
162
Issue
8
Pages
1731-1742
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1586434302
Cited by
57
References
4
FWCI
1.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Kalopanaxsaponin A ameliorates experimental colitis in mice by inhibiting IRAK‐1 activation in the NF‐κB and MAPK pathways. https://app.cochat.ai/papers/10.1111/j.1476-5381.2010.01195.x
The paper
Joh, E., & Kim, D. (2011). Kalopanaxsaponin A ameliorates experimental colitis in mice by inhibiting IRAK‐1 activation in the NF‐κB and MAPK pathways. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2010.01195.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.